At the 71st annual American College of Cardiology (ACC) 2022 meeting, results were presented from MAVA-LTE, the ongoing five-year study of mavacamten in obstructive hypertrophic cardiomyopathy (oHCM). Based on these results, mavacamten will likely dominate the oHCM market as the first-in-class cardiac myosin inhibitor and rapidly steal market share from the non-specific therapies that are part of the current treatment regimen, says GlobalData, a leading data and analytics company.

Mavacamten is a selective cardiac myosin inhibitor that decreases the contractility of the heart muscle by inhibiting myosin and actin, proteins in the muscle, from interconnecting and inducing the contracting motion.

Akash Patel, Pharma Analyst at GlobalData, comments: “Mavacamten’s ability to continually demonstrate a significant improvement in patients’ quality of life will undoubtedly strengthen its impending market launch. Currently, it’s in pre-registration for hypertrophic cardiomyopathy (HCM) in the US. With the benefits that mavacamten provides, it will likely achieve a dominant share of the oHCM market. As the first oHCM-targeted therapy, it will likely have a significant competitive share of the oHCM market from the currently marketed non-specific therapies.”

HCM is a primary myocardial disorder that results from unexplained left ventricular (LV) hypertrophy that is often caused by pathogenic variants in sarcomeric genes. There are two major types of HCM: oHCM and non-oHCM. In oHCM, blood flow is blocked or severely restricted due to stiffening of the left ventricular wall as a result of HCM.

Patel adds: “Several significant efficacy outcomes were observed for this trial, including that both resting, and Valsalva left ventricular outflow tract (LVOT), (Valsalva is a breathing technique that forces heart rate to slow down), improved rapidly within four weeks following the onset of treatment with mavacamten. This improvement was sustained until 84 weeks and a reduction in left ventricular ejection fraction LVEF was also observed.”